In view of the fact that there is evidence to show that mTor inhibitor rapamycin has been reported to be associated with reduction of the volume of angiomyolipoma (AML), perhaps it would be a good idea to give all patients who have undergone embolization of resection of angiomyolipoma (AML) as adjuvant treatment. The gene discussed is MTOR; the disease is acute myeloid leukemia.